Samsung Bioepis announced on April 23 that it has received final marketing authorization from the European Commission (EC) for Pyzchiva (project name SB17, ustekinumab), a biosimilar to Stelara. Pyzchiva’s active substance name is ustekinumab.Pyzchiva is the fourth autoimmune disease treatment devel
Samsung Bioepis announced on March 15 that it has sealed a partnership deal with Yuhan Corp. to sell Adalloce (substance name: adalimumab), a treatment for autoimmune diseases, in Korea.Adalloce is a biosimilar to Humira, the world's No. 1 drug in terms of sales (23 trillion won), and is used to
The author is an analyst with NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. With higher global demand for biosimilars and healthy earnings at global leading bio CDMO players translating into accompanying share price hikes, we believe that the time is ripe for a need to
South Korean biosimilar drugs are contributing to medical expense reduction in the United Kingdom. These drugs are the same as original medicines in efficacy and safety but are more than 30 percent cheaper.The expenses for medicines and medical supplies fell 294 million pounds (US$367.32 million or
The world's top-selling drug Humira is about to lose its place due to newly launched biosimilars. Although AbbVie has introduced a new price policy for Humira, market analysts report that the drug’s market share has rapidly fallen due to competition from biosimilars, including Samsung Bioepis’ I
Samsung Bioepis' Imraldi, a biosimilar to Humira, gained 62 percent of the market in Germany as of Nov. 13, according to a tally released by medical market researcher IQVIA on Dec. 10. The figure was reached less than a month after the South Korean drug company launched Imraldi in Europe on Oct.
Samsung Bioepis and other biosimilar developers are on alert as the U.S. biotech company AbbVie has cut down the price of Humira in Europe by 80%.Humira, an autoimmune disease treatment, is the top-selling drug in the global market, with global sales reaching 20 trillion won (US$18 billion) last yea
Samsung Bioepis has launched “Imraldi,” a biosimilar to Humira, the world's top-selling biopharmaceutical from AbbVie, in Europe.Samsung Biotepis CEO Han Seung-jin said on Oct. 17, "With the launch of Imraldi, Samsung Bioepis has successfully rolled out all of its four biosimilars that have been
Samsung BioLogics Co.’s market value has surpassed that of its biosimilar rival Celltrion for the first time as its stock prices reach an all-time high.At 9:24 a.m. on April 10, Samsung BioLogics’ shares gained 5.16 percent to trade at 591,000 won (US$553.37) on the KOSPI. The company’s stock price
South Korea is situated on the periphery of the global pharmaceutical industry map. The global drug market reached US$1.1 trillion (1,244 trillion won) as of last year, the South Korean market stood at 21.7 trillion won (US$19.19 billion), accounting for a 0.012 percent of the total. There are no So
According to industry sources, multinational pharmaceutical companies are hindering the growth of the global biosimilar market by using their patents.AbbVie’s Humira has been the best-selling medicine in the world for years and the American pharmaceutical company recorded US$16 billion in sales last